Fosun Pharmaceutical Risk Reward Update: Maintain Overweight, H-share Target Price HK$32.00

Overview

This report is Morgan Stanley's risk-reward update on Fosun Pharmaceutical (2196.HK/600196.SS). After incorporating 2025 results, the report raises its 2026-28 revenue forecasts by 3%, mainly driven by higher innovative drug sales and Rmb800 million of recurring licensing income, while also adjusting operating expenses based on historical trends. The report maintains an Overweight rating and sets an H-share target price of HK$32.00.

Core views

The core view is that Fosun Pharmaceutical is driving an operational recovery through new drug ramp-up and divestment of non-core businesses. As an integrated healthcare company, it covers multiple segments of China's healthcare value chain, but profits are still mainly contributed by the pharmaceutical business; its mixed business structure may cause the value of its innovative pipeline to be underestimated. Morgan Stanley expects the company can still achieve its 2026-27 ESOP net profit targets.

Analysis framework

The report adopts an SOTP valuation framework and combines bull, base, and bear scenarios for risk-reward analysis. Innovative drugs are valued at Rmb75 billion, the generics portfolio at Rmb19 billion, Sinopharm Group at 5x 2026e P/E, the medtech segment at Rmb11 billion, and healthcare services at 5x EV/EBITDA.

Methodology notes

• Valuation frameworkSOTP

  Sum-of-the-parts valuation

  Innovative drugs, generics, Sinopharm Group, medtech, and healthcare services are valued separately and then summed to reflect the value of Fosun Pharmaceutical's multi-business structure.

• Scenario analysisRisk Reward

  Bull, base, and bear scenarios

  The report sets bull, base, and bear scenarios of HK$55.00, HK$32.00, and HK$15.50, respectively, using variables such as the speed of new drug ramp-up, recovery in the device and services segments, and the probability of success of the innovative pipeline to assess upside and downside potential.

• Earnings forecastMorgan Stanley ModelWare

  Internal forecasting model

  The report states that, unless otherwise indicated, the relevant metrics are based on the Morgan Stanley ModelWare framework and Morgan Stanley Research estimates.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Fosun Pharmaceutical (2196.HK)

  Covered H-share security

  Strengths

  Overweight rating, target price of HK$32.00, with innovative drug ramp-up and non-core business divestments as the main positive drivers.

  Weaknesses

  Profit contribution remains concentrated in the pharmaceutical business, while the device and services businesses have yet to generate meaningful profit contribution.

  Comparison

  Consensus rating distribution shows 67% Overweight, 33% Equal-weight, and 0% Underweight.

  Risks

  Innovative drug ramp-up below expectations, slower-than-expected recovery in devices and services, policy changes, and quarterly earnings volatility.

• Fosun Pharmaceutical (600196.SS)

  A-share security of the same company

  Strengths

  The report discloses an A-share target price of Rmb40.00, and both A-shares and H-shares benefit from the company's new-drug and business-recovery thesis.

  Weaknesses

  The target price is affected by assumptions such as SOTP segment valuation and exchange rates, and A/H share valuation performance may diverge.

  Comparison

  The H-share target price is HK$32.00, while the A-share target price is Rmb40.00.

  Risks

  Changes in valuation assumptions, exchange-rate changes, and the pace of policy and operational recovery.

• Innovative drugs

  Core growth driver and important SOTP segment

  Strengths

  The report values innovative drugs at Rmb75 billion and believes the innovative pipeline may be undervalued due to the mixed business structure.

  Weaknesses

  There is uncertainty around the probability of success and commercialization pace of the innovative pipeline.

  Comparison

  The bull case depends on faster ramp-up of innovative drugs; the bear case assumes a significant decline in the pipeline's PoS and internalization potential.

  Risks

  Approval delays, sales ramp-up below expectations, and lower-than-expected volume/price changes from NRDL implementation.

• Medtech and healthcare services

  Recovery-type business segments

  Strengths

  In the bull case, faster recovery in the device and services segments helps drive net profit growth.

  Weaknesses

  The report notes that devices and services currently do not yet contribute profits.

  Comparison

  Medtech is valued at Rmb11 billion, while healthcare services are valued at 5x EV/EBITDA.

  Risks

  Slower demand recovery, margin improvement falling short of expectations, and uncertainty around the pace of non-core business disposals.

Key data

• Stock ratingOverweightMorgan Stanley maintains an Overweight rating on Fosun Pharmaceutical.
• Industry viewAttractiveThe industry view disclosed in the report is Attractive.
• H-share target priceHK$32.00Reduced from the previous HK$33.00; the chart shows implied upside of +59.20% relative to the HK$20.10 closing price.
• A-share target priceRmb40.00The text discloses that under the SOTP framework, the A-share target price is reduced to Rmb40.00.
• Current share priceHK$20.10H-share closing price as of April 21, 2026.
• Bull caseHK$55.00Assumes pharmaceutical net profit CAGR of about 25% for 2024-28e, faster ramp-up of innovative drugs, and quicker recovery in the device and services segments.
• Base caseHK$32.0020.0x 2026e EPS, reflecting about 17% net profit CAGR for 2024-28e.
• Bear caseHK$15.50Assumes net profit CAGR of about 10% for 2024-28e, weaker-than-expected innovative drug ramp-up, and slower recovery in device and services.
• 2026e EPSRmb1.49Updated 2026e EPS; previous value was Rmb1.50.
• 2027e EPSRmb1.79Updated 2027e EPS; previous value was Rmb1.81.
• 2028e EPSRmb2.04Updated 2028e EPS; previous value was Rmb1.97.
• Global revenue exposureMainland China 70-80%The chart shows Mainland China as the main source of revenue, with Europe excluding the UK at 10-20%, and North America and MEA each at 0-10%.

Impact & implications

The report has a positive investment implication: even though the target price is slightly adjusted from the previous level, the base-case scenario still shows substantial upside. The key re-rating factors for Fosun Pharmaceutical are delivery of innovative drug sales, sustainability of licensing income, improvement in cash flow from non-core asset divestments, and whether the device and services businesses can return to profitability.

Risks

• Innovative drug ramp-up weaker than expected.
• Recovery in the device and services segments slower than expected.
• Probability of success and internalization potential of the innovative pipeline below assumptions.
• Changes in government policy may affect pricing, market access, and profitability.
• There is uncertainty around the approval progress of new products by the CFDA and US FDA.
• The volume uplift from NRDL implementation may fall short of expectations.
• Quarterly earnings volatility may affect the rating and target price.
• Morgan Stanley discloses existing or prospective investment banking relationships with some covered companies, and investors should note potential conflicts of interest.

What to watch

• The sales ramp-up pace of innovative drugs and biosimilars.
• The sustainability and realization pace of the Rmb800 million recurring licensing income.
• Progress toward achieving the 2026-27 ESOP net profit targets.
• The actual contribution of non-core business divestments to cash flow improvement.
• Whether the device and healthcare services segments can recover from losses or low-profit status.
• Progress in CFDA and US FDA approvals for new products.
• Changes in sales volume after NRDL implementation.
• Differences between quarterly results and Morgan Stanley forecasts and market consensus.